Valentina Rossi, PD, MD, MSc, Specialist at Cardiology, University Hospital Zurich shared a post on LinkedIn:
“My first manuscript within my PhD program at the Maastricht University about Immune-Mediated Cardiomyopathies and Their Impact on Long-Term Outcomes has been just published in the European Journal of Heart Failure!
Key findings include:
- Higher Risk of Adverse Events: Patients with ID-CMP face a significantly higher risk of major adverse cardiovascular events (MACE), including cardiac mortality, heart failure hospitalization, and life-threatening arrhythmias, compared to non-immune DCM patients.
- Inflammation as a Key Factor: Persistent myocardial inflammation, evidenced by elevated immune cell counts (CD3+, CD45+, CD68+), is linked to worse outcomes, independent of genetic factors or left ventricular ejection fraction (LVEF) recovery.
- Similar LVEF Trajectories: Despite worse outcomes, ID-CMP patients show comparable long-term LVEF recovery to nonID-CMP patients, suggesting factors beyond systolic function drive disease progression.
- Validation Across Cohorts: Findings were confirmed in an external validation cohort, highlighting the need for tailored management and enhanced cardiovascular surveillance for ID-CMP patients.
This study underscores the importance of addressing inflammation and immune mechanisms in cardiomyopathy management.”
Title: Clinical characteristics and outcomes of cardiomyopathies related to immune-mediated diseases
Authors: Valentina A. Rossi, Maurits A. Sikking, Alessandro Folgheraiter, Carola Pio Loco, Fernando Dominguez, Bastien S. C. Nihant, Sophie L. V. M. Stroeks, Michiel T. H. M. Henkens, Nerea Mora-Ayestarán, Noemí Ramos-López, Gianfranco Sinagra, Pablo Garcia-Pavia, Frank Ruschitzka, Marco Merlo, Job A. J. Verdonschot, Stephane R. B. Heymans
Read The Full Article
Other articles about Cardiomyopathy on OncoDaily.